US20080227696A1 - Single branch heparin-binding growth factor analogs - Google Patents

Single branch heparin-binding growth factor analogs Download PDF

Info

Publication number
US20080227696A1
US20080227696A1 US11/359,173 US35917306A US2008227696A1 US 20080227696 A1 US20080227696 A1 US 20080227696A1 US 35917306 A US35917306 A US 35917306A US 2008227696 A1 US2008227696 A1 US 2008227696A1
Authority
US
United States
Prior art keywords
heparin
growth factor
fgf
binding
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/359,173
Other languages
English (en)
Inventor
Kazuyuki Takahashi
Paul O. Zamora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosurface Engineering Technologies Inc
Original Assignee
Biosurface Engineering Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosurface Engineering Technologies Inc filed Critical Biosurface Engineering Technologies Inc
Priority to US11/359,173 priority Critical patent/US20080227696A1/en
Priority to AU2006216676A priority patent/AU2006216676A1/en
Priority to EP06735882A priority patent/EP1855706A4/en
Priority to CA002598688A priority patent/CA2598688A1/en
Priority to JP2007556427A priority patent/JP4897708B2/ja
Priority to PCT/US2006/006397 priority patent/WO2006091727A2/en
Priority to US11/361,090 priority patent/US7671012B2/en
Assigned to BIOSURFACE ENGINEERING TECHNOLOGIES, INC. reassignment BIOSURFACE ENGINEERING TECHNOLOGIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TAKAHASHI, KAZUYUKI, ZAMORA, PAUL O.
Publication of US20080227696A1 publication Critical patent/US20080227696A1/en
Priority to US12/786,256 priority patent/US8101570B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to the field of synthetic peptides and analogs of heparin-binding growth factors, including homodimeric synthetic heparin-binding growth factor analogs wherein two sequences are branched from a single branch point, the single branch point including at least one trifunctional amino acid residues, which branch point is further covalently bonded to a heparin-binding sequence.
  • the invention further relates to the clinical uses of such analogs as soluble drugs and as coatings for medical devices.
  • heparin-binding growth factors constitute a large class of growth factors that includes the 23 fibroblast growth factors identified to date (FGFs 1-23), HBBM (heparin-binding brain mitogen), HB-GAF (heparin-binding growth associated factor), HB-EGF (heparin-binding EGF-like factor) HB-GAM (heparin-binding growth associated molecule), TGF- ⁇ (transforming growth factor- ⁇ ), TGF- ⁇ s (transforming growth factor- ⁇ s), PDGF (platelet-derived growth factor), EGF (epidermal growth factor), VEGF (vascular endothelial growth factor), IGF-1 (insulin-like growth factor-1), IGF-2 (insulin-like growth factor-2), HGF (hepatocyte growth factor), IL-1 (interleukin-1), IL-2 (interleukin-2), IFN- ⁇ (interferon- ⁇ ), IFN- ⁇ (interferon- ⁇ ), TNF- ⁇ (tumor necrosis factor- ⁇
  • Peptides from natural HBGFs that bind heparin-binding growth factor receptors have been identified. See for example Ray et al., Proc. Natl. Acad. Sci. USA 94:7047-7052 (1997). These authors demonstrated that two amino acid sequences from FGF-2 are sufficient to block the mitogenic activity of FGF-2 on neural progenitor cells.
  • the first peptide is a ten amino acid sequence, from amino acids 65-74, the second peptide extends from amino acids 115-129.
  • HBGFR heparin-binding growth factor receptor
  • HBGFs useful in prevention or therapy of a wide range of diseases and disorders may be purified from natural sources or produced by recombinant DNA methods, however, such preparations are expensive and generally difficult to prepare.
  • heparin-binding growth factor analogs For example, natural PDGF occurs as an A chain and a B chain arranged in head-to-head (AA or BB) homodimers, or (AB or BA) heterodimers.
  • AA or BB head-to-head
  • AB or BA BA
  • U.S. Pat. No. 6,350,731 to Jehanli et al. discloses PDGF analogs in which two synthetic PDGF receptor-binding domains are covalently linked through a polyglycine or an N-(4-carboxy-cyclohexylmethyl)-maleimide (SMCC) chain to mimic the natural active polypeptide dimer.
  • SMCC N-(4-carboxy-cyclohexylmethyl)-maleimide
  • U.S. Pat. No. 6,235,716 to Ben-Sasson discloses analogs of angiogenic factors.
  • the analogs are branched multivalent ligands that include two or more angiogenic homology regions connected by a multilinker backbone.
  • U.S. Pat. No. 5,770,704 discloses conjugates for activating receptor tyrosine kinases, cytokine receptors and members of the nerve growth factor receptor superfamily.
  • the conjugates include at least two ligands capable of binding to the cognate receptor, so that the binding of the respective ligands induces oligomerization of these receptors.
  • the ligands disclosed in the '704 patent are linked by covalent attachment to various nonproteinaceous polymers, particularly hydrophilic polymers, such as polyvinylalcohol and polyvinylpyrrolidone, and the polyvinylalkene ethers, including polyethylene glycol and polypropylene glycol.
  • the ligands include hepatocyte growth factor (HGF) peptide variants that each bind HGF receptor, thereby causing receptor dimerization and activation of the biological activity of the HGF receptor dimer.
  • HGF hepatocyte growth factor
  • U.S. Pat. No. 6,284,503 discloses a composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces and hydrophobic coated surfaces for cell adhesion, cell growth, cell sorting and biological assays.
  • the composition is a biomolecule conjugated to a reactive end group activated polymer.
  • the end group activated polymer includes a block copolymer surfactant backbone and an activation or reactive group.
  • the block copolymer may be any surfactant having a hydrophobic region capable of adsorbing onto a hydrophobic surface, and a hydrophilic region which extends away from the surface when the hydrophobic region is adsorbed onto the hydrophobic surface.
  • biomolecules that may be conjugated to the end group activated polymer include natural or recombinant growth factors, such as PDGF, EGF, TGF ⁇ , TGF ⁇ , NGF, IGF-I, IGF-II, GH and GHRF, as well as multi-CSF(II-3), GM-CSF, G-CSF, and M-CSF.
  • natural or recombinant growth factors such as PDGF, EGF, TGF ⁇ , TGF ⁇ , NGF, IGF-I, IGF-II, GH and GHRF, as well as multi-CSF(II-3), GM-CSF, G-CSF, and M-CSF.
  • compositions that include homologs and analogs of fibroblast growth factors (FGFs). See for example U.S. Pat. No. 5,679,673 to Lappi and Baird; U.S. Pat. No. 5,989,866 to Deisher et al. and U.S. Pat. No. 6,294,359 to Fiddes et al.
  • FGFs fibroblast growth factors
  • a series of patent applications to Kochendoerfer et al. disclose polymer-modified proteins, including synthetic chemokines and erythropoiesis stimulating proteins. See, for example, International Publications WO 02/04105, WO 02/19963 and WO 02/20033. These include chemically ligated peptide segments of a polypeptide chain of a synthetic erythropoiesis protein, such that a polypeptide chain results, with a water soluble polymer attached at one or more glycosylation sites on the protein. These applications also disclose synthetic chemokines, which are also polymer modified, and are asserted to be antagonists. However, heparin-binding domains are not disclosed. Other erythropoietin mimetics are known, such as those disclosed in U.S. Pat. Nos. 5,773,569 and 5,830,851 to Wrighton et al.
  • oligomerization domain refers to a composition consisting of fusion proteins having FGF receptor affinity linked to an “oligomerization domain”, either directly or through a linking group.
  • the oligomerization domain ranges in length from about 20 to 300 residues, and includes constructs such as transcription factors, Fc portions of IgG, leucine zippers and the like.
  • the oligomerization domains disclosed are homodimeric domains, wherein a single FGF receptor affinity fusion protein is linked to a single domain, such as a leucine zipper, which in turn is linked to a similar molecule by means of cysteine residues at both the amino and carboxy termini of the leucine zippers, such that two parallel leucine zippers, each with a single FGF receptor affinity fusion protein, are cross-linked by means of disulfide bonds.
  • fusion proteins may include a heparin binding domain, such as the use of jun as a multimerization domain, which is asserted to be a heparin binding domain.
  • compositions disclosed by Ballinger and Kavanaugh are all composed of a single receptor-binding sequence covalently attached to an oligomerization domain, whereby two or more similar oligomerization domains, each with a single receptor-binding sequence, are conjoined by means of either an association provided by the oligomerization domain, or alternatively, are chemically cross-linked to provide for the covalent bonding of the individual components.
  • a series of applications with some inventors in common including U.S. patent application Ser. No. 10/644,703, entitled Synthetic Heparin-Binding Growth Factor Analogs, filed on Aug. 19, 2003, and U.S. patent application Ser. No.
  • compositions each include a receptor-binding domain.
  • none of the disclosed compositions further include two receptor-binding domains linked to a single residue through a terminal group and a side chain group of the single residue.
  • new peptide analogs of HBGFs particularly for those that function as agonists, and preferably those that contain two receptor-binding domains specific for a HBGFR.
  • cost-effective synthetic peptide agonists of heparin-binding growth factor receptors particularly synthetic heparin-binding growth factor agonists useful for coating medical devices and as soluble biologics, and as pharmaceutical agents for treating a variety of conditions.
  • One aspect of the present invention is a heparin-binding growth factor analog of formula I:
  • each X is a peptide chain that (i) has a minimum of three amino acid residues, (ii) has a maximum of about fifty amino acid residues, and (iii) binds a heparin-binding growth factor receptor (HBGFR);
  • R 1 is a single trifunctional amino acid residue covalently bonded to each X;
  • Each R 2 is independently a linker comprising a chain from 0 to about 20 backbone atoms including carbon, oxygen, sulfur, nitrogen and mixtures thereof covalently bonded to R 1 and X;
  • Each R 3 is hydrogen (H) such that the terminal group is NH 2 , or is an acyl group with a linear or branched C 1 to C 17 alkyl, aryl, heteroaryl, alkene, alkenyl or aralkyl chain including an N-terminus NH 2 , NH3+, or NH group or a corresponding acylated derivative;
  • R 4 is OH such that the terminal group is a carboxyl, NH 2 , an acyl group with a linear or branched C 1 to C 17 alkyl, aryl, heteroaryl, alkene, alkenyl or aralkyl chain including an N-terminus NH 2 , NH 3 + , or NH group or a corresponding acylated derivative, or NH—R 3 ;
  • Y is a linker comprising a chain from 0 to about 50 backbone atoms covalently bonded to R 1 and Z;
  • Z is a non-signaling peptide chain that includes a heparin binding domain, comprising an amino acid sequence that comprises (i) a minimum of one heparin binding motif, (ii) a maximum of about ten heparin binding motifs, and (iii) a maximum of about thirty amino acids.
  • Y further comprises a linker that (i) is hydrophobic, (ii) comprises a chain of a minimum of about 9 and a maximum of about 50 atoms, and (iii) is not found in the natural ligand of the heparin-binding growth factor receptor (HBGFR) which X binds.
  • HBGFR heparin-binding growth factor receptor
  • heparin-binding growth factor analog of formula I-IV has an avidity for heparin such that the synthetic heparin-binding growth factor analog binds heparin in 0.15 M NaCl, but is eluted by 1 M NaCl.
  • Another aspect of the present invention provides a heparin-binding growth factor analog of formula II:
  • R 1 is a diamine amino acid. All other features are as represented for formula I.
  • R 1 of the heparin-binding growth factor analog of formula II is an L- or D-diamine amino acid residue selected from the group consisting of 2,3 diamino propionyl amino acid, 2,4 diamino butylic amino acid, lysine and ornithine.
  • Another aspect of the present invention provides a heparin-binding growth factor analog of formula III:
  • Yet another aspect of the present invention provides a heparin-binding growth factor analog of of formula IV:
  • R 1 is a trifunctional amino acid wherein the side chain of R 1 comprises a reactive sulfhydryl
  • R 2 comprises a trifunctional amino acid wherein the side chain comprises a reactive sulfhydryl, wherein R 2 is covalently bonded to R 1 by a disulfide bond.
  • R 1 and R 2 are each independently an L- or D-3-mercapto amino acid selected from the group consisting of L- or D-cysteine, L- or D-penicillamine, 3-mercapto phenylalanine, and a derivative of any of the foregoing.
  • Another aspect of the present invention provides for a heparin-binding growth factor analog of formula V:
  • Prg Grp is OH or a carboxy terminus protecting group
  • C is carbon, H is hydrogen, N is nitrogen, O is oxygen and S is sulfur. All other features are as represented for formula I.
  • Still another aspect of the present invention provides a heparin-binding growth factor analog of formula VI:
  • R 1 is a trifunctional amino acid wherein the side chain comprises a first reactive group
  • R 2 comprises a trifunctional amino acid wherein the side chain comprises a second reactive group, wherein R 2 is covalently bonded to R 1 by a covalent bond between the first reactive group and the second reactive group. All other features are as represented for formula I.
  • X and Z of any of formulas I-VI are synthetic peptide chains.
  • Still another aspect of the present invention provides a heparin-binding growth factor analog comprising a synthetic peptide having two sequences branched from a single residue, the two sequences being the same and binding specifically to a heparin-binding growth factor receptor, and a sequence comprising a non-growth factor heparin-binding sequence covalently bonded to the single residue.
  • the single residue comprises a trifunctional amino acid residue.
  • non-growth factor heparin-binding sequence is covalently bonded to the single residue by means of a linker.
  • N still another aspect provides a heparin-binding growth factor analog having a backbone chain from 2 to about 50 atoms.
  • Y of any of formulas I-VI comprises between one and about thirty-three ethylene glycol units.
  • Y of any of formulas I-VI comprises a branched or unbranched, saturated or unsaturated alkyl chain of between one and about twenty carbon atoms.
  • Y of any of formulas I-VI comprises [NH 2 —(CH 2 ) p CO] q wherein p is from 1 to about 10 and q is from 1 to about 20.
  • Y of any of formulas I-VI comprises a peptide sequence comprising from one to about 16 Gly residues.
  • Z of any of formulas I-VI is BxBB or BBBxxB, wherein each B is independently lysine, arginine, ornithine, or histidine, and each x is a independently a naturally occurring amino acid.
  • Z of any of formulas I-VI comprises at least two heparin-binding motifs.
  • the covalent bonds between R 1 and Y of any of formulas I-VI comprise an amide, disulfide, thioether, Schiff base, reduced Schiff base, imide, secondary amine, carbonyl, urea, hydrazone or oxime bond.
  • covalent bonds between R 1 and each X of any of formulas I-VI comprise an amide, disulfide, thioether, Schiff base, reduced Schiff base, imide, secondary amine, carbonyl, urea, hydrazone or oxime bond.
  • the covalent bonds between Y and Z of any of formulas I-VI comprise an amide, disulfide, thioether, Schiff base, reduced Schiff base, imide, secondary amine, carbonyl, urea, hydrazone or oxime bond.
  • X in any of formulas I-VI is any of SEQ ID NO:7 to SEQ ID NO:107, a portion thereof, a homolog thereof, or a homolog of a portion thereof, and Z comprises any of SEQ ID NO:1 to SEQ ID NO:6.
  • the R 2 of any of formulas I-VI comprises between one and about three amino acid residues selected from the group consisting of glycine, a straight chain amino carboxylic acid, a bifunctional amino-PEG-acid spacer and combinations thereof.
  • Y of any of formulas I-VI comprises between one and about ten amino acid residues selected from the group consisting of glycine, a linear chain amino carboxylic acid, a bifunctional amino-PEG-acid spacer and combinations thereof.
  • X of any of formulas I-VI comprises an amino acid sequence found in any of FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, FGF-15, FGF-16, FGF-17, FGF-18, FGF-19, FGF-20, FGF-21, FGF-22, FGF-23, HBBM (heparin-binding brain mitogen), HB-GAF (heparin-binding growth associated factor), HB-EGF (heparin-binding EGF-like factor) HB-GAM (heparin-binding growth associated molecule, also known as pleiotrophin, PTN, HARP), TGF- ⁇ (transforming growth factor- ⁇ ), TGF- ⁇ s (transforming growth factor- ⁇ s), VEGF (vascular endothelial growth factor), EGF (epidermal growth factor), IGF-1 (insulin
  • a pharmaceutical composition comprises the heparin-binding growth factor analog of any of formulas I-VI or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier.
  • FIG. 1 illustrates an RP-HPLC profile for the SD1-1 analog according to one embodiment of the present invention.
  • FIG. 2 illustrates a graph of SDF-1 and SD1-1 analog concentration dependent induction of cell proliferation according to one embodiment of the present invention.
  • FIG. 3 illustrates a bar graph of SDF-1 and SD1-1 analog induced cell migration according to one embodiment of the present invention.
  • FIG. 4 illustrates a RP-HPLC profile for a PDGF analog according to one embodiment of the present invention according to one embodiment of the present invention.
  • FIG. 5 illustrates results from a cell proliferation assay with PDGF analog PBA2-1 according to one embodiment of the present invention.
  • FIG. 6 illustrates analysis by RP-HPLC of PBA2-1C analog according to one embodiment of the present invention according to one embodiment of the present invention.
  • FIG. 7 illustrates the effect of analog PBA2-1 on cell proliferation according to one embodiment of the present invention according to one embodiment of the present invention.
  • FIG. 8 illustrates a dose-dependant suppression of the activity of BMP-7 by B7A1-6 analog according to one embodiment of the present invention.
  • FIG. 9 illustrates augmented cellular growth by GCSF-1 analog according to one embodiment of the present invention.
  • Each synthetic HBGF analog of the invention contains two substantially similar sequences (homodimeric sequences) that are analogs of a particular HBGF that binds to a HBGFR, or alternatively that bind to a HBGFR without being an analog of any particular HBGF.
  • the homodimeric sequences may be derived from any portion of a HBGF.
  • the synthetic HBGF analog may be an analog of a hormone, a cytokine, a lymphokine, a chemokine or an interleukin, and may bind to any HBGFR for any of the foregoing.
  • HBGFs include any growth factor that binds selectively to heparin.
  • the HBGF can be any of the known FGFs (FGF-1 to FGF-23), Activin-A, HBBM (heparin-binding brain mitogen), HB-GAF (heparin-binding growth associated factor), HB-EGF (heparin-binding EGF-like factor) HB-GAM (heparin-binding growth associated molecule, also known as pleiotrophin, PTN, HARP), TGF- ⁇ (transforming growth factor- ⁇ ), TGF- ⁇ s (transforming growth factor- ⁇ s), VEGF (vascular endothelial growth factor), EGF (epidermal growth factor), IGF-1 (insulin-like growth factor-1), IGF-2 (insulin-like growth factor-2), PDGF (platelet derived growth factor), RANTES, SDF
  • agents of the invention can be modified through the introduction of appropriate binding sequences to direct analogs of growth factors, cytokines, interleukins, and chemokines, which do not normally bind to heparin, to have heparin-binding affinity.
  • the synthetic HBGF analog of the present invention consists essentially of the molecule of any one of formulas I to VI, i.e. the molecule of any one of formula I to VI is the major active component in the synthetic HBGF analog composition.
  • the heparin-binding growth factors of formulas I to VI include amino acid residues, and optionally the region Y includes amino acid residues.
  • An amino acid residue is defined as —NHRCO—, where R can be hydrogen or any organic group.
  • the amino acids can be D-amino acids or L-amino acids. Additionally, the amino acids can be ⁇ -amino acids, ⁇ -amino acids, ⁇ -amino acids, or ⁇ -amino acids and so on, depending on the length of the carbon chain of the amino acid.
  • amino acids of the X, Y and Z component regions of the synthetic HBGF analogs of the invention can include any of the twenty amino acids found naturally in proteins, i.e. alanine (Ala, A), arginine (Arg, R), asparagine (Asn, N), aspartic acid (Asp, D), cysteine (Cys, C), glutamic acid (Glu, E), glutamine (Gln, Q), glycine (Gly, G), histidine (His, H), isoleucine, (Ile, I), leucine (Leu, L), lysine (Lys, K), methionine (Met, M), phenylalanine (Phe, F), proline (Pro, P), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y), and valine (Val, V).
  • alanine Al, A
  • amino acids of the X, Y and Z component regions of the synthetic HBGF analogs of the invention can include any of the naturally occurring amino acids not found naturally in proteins, e.g. ⁇ -alanine, betaine (N,N,N-trimethylglycine), homoserine, homocysteine, ⁇ -amino butyric acid, ornithine, and citrulline.
  • amino acids of the X, Y and Z component regions of the synthetic HBGF analogs of the invention can include any of the non-biological amino acids, i.e. those not normally found in living systems, such as for instance, a straight chain amino carboxylic acid not found in nature.
  • straight chain amino carboxylic acids include 6-aminohexanoic acid, 7-aminoheptanoic acid, 9-aminononanoic acid and the like.
  • two X regions are covalently linked to R 1 , either directly or through an R 2 group, where R 1 is a trifunctional amino acid residue, preferably a trifunctional alpha amino acid residue. It is to be appreciated that such covalent bonds may be to any chemically permitted functional group.
  • the trifunctional amino acid residue is an amino acid with a reactive sulfhydryl side chain, such as cysteine
  • a reactive sulfhydryl side chain such as cysteine
  • one X is covalently bonded through the N-terminus amine group
  • the second X is covalently bonded through the reactive sulfhydryl side chain, such as where R 2 includes a second cysteine residue covalently liked through a disulfide bond
  • Y is covalently bonded to the second cysteine through the C-terminus carboxyl group thereof.
  • R 1 is a diamine trifunctional amino acid residue, wherein R 1 is covalently bonded to Y through the carboxyl group of R 1 , and the two X groups are covalently bonded to R 1 through the alpha amine and the epsilon amine of the side chain.
  • Preferred groups for R 1 thus include 2,3 diamino propionyl amino acid, 2,4 diamino butylic amino acid, lysine or ornithine.
  • Particularly useful amino acid sequences as X regions of formulas I to VI include homologs of fragments of naturally occurring HBGFs that differ from the amino acid sequences of natural growth factor in only one or two or a very few positions.
  • Such sequences preferably include conservative changes, where the original amino acid is replaced with an amino acid of a similar character according to well known principles; for example, the replacement of a non-polar amino acid such as alanine with valine, leucine, isoleucine or proline; or the substitution of one acidic or basic amino acid with another amino acid of the same acidic or basic character.
  • the X regions of the synthetic HBGF analog can include an amino acid sequence that shows no detectable homology to the amino acid sequence of any HBGF.
  • Peptides or growth factor analogs useful as components of the X region of the synthetic analogs of the present invention, that have little or no amino acid sequence homology with the cognate growth factor and yet bind HBGFRs may be obtained by any of a wide range of methods, including for instance, selection by phage display. See as an example: Sidhu et al. Phage display for selection of novel binding peptides. Methods Enzymol. 328:333-63 (2000).
  • the X region of the synthetic HBGF analogs of the invention can have any length that includes an amino acid sequence that effectively binds an HBGFR.
  • the X regions of the synthetic HBGF analogs have a minimum length of at least approximately three amino acid residues. More preferably, the X regions of the synthetic HBGF analogs have a minimum length of at least approximately six amino acid residues. Most preferably the X regions of the synthetic HBGF analogs have a minimum length of at least approximately ten amino acid residues.
  • the X regions of the synthetic HBGF analogs of the invention preferably also have a maximum length of up to approximately fifty amino acid residues, more preferably a maximum length of up to approximately forty amino acid residues, and most preferably a maximum length of up to approximately thirty amino acid residues.
  • the R 2 regions of formulas I, IV or VI can include a chain of atoms or a combination of atoms that form a chain.
  • the chains are chains of carbon atoms, that may also optionally include oxygen, nitrogen or sulfur atoms, such as for example chains of atoms formed from amino acids (e.g. amino acids found in proteins, as listed above; naturally occurring amino acids not found in proteins, such as ornithine and citrulline; or non natural amino acids, such as amino hexanoic acid; or a combination of any of the foregoing amino acids).
  • amino acids e.g. amino acids found in proteins, as listed above; naturally occurring amino acids not found in proteins, such as ornithine and citrulline; or non natural amino acids, such as amino hexanoic acid; or a combination of any of the foregoing amino acids.
  • agents such as polyethylene glycol (PEG), polyethylene oxide (PEO), amino polyethylene glycol, bis-amine-PEG, and other variants of polyethylene glyco
  • the chain of atoms of the R 2 region of formulas I, IV or VI is covalently attached to X and R 1 .
  • the covalent bonds can be, for example, a peptide bond or other amide bond, or a thioether or ester bond.
  • the R 2 region preferably includes a chain of a minimum of about three backbone atoms.
  • the covalent bonds are peptide bonds
  • the R 2 region may be formed from a chain of at least one, at least two or at least three amino acids.
  • the R 2 region may further include a cross-linking moiety.
  • the R 2 region can be a linker consisting of a sulfhydryl reactive homo-bifunctional cross linker and a second Cys, or alternatively can include a hetero-bifunctional cross-linker, such as a cross-linker linking to the sulflhydryl on the R 1 side chain and carboxyl group of X.
  • the Y region of any of formulas I to VI is a linker that is sufficiently hydrophobic to non-covalently bind the HBGF analog to a polystyrene or polycaprolactone surface, or the like.
  • the Y region may bind to other hydrophobic surfaces, particularly the hydrophobic surfaces formed from materials used in medical devices. Such surfaces are typically hydrophobic surfaces.
  • suitable surfaces include but are not limited to those formed from hydrophobic polymers such as polycarbonate, polyester, polypropylene, polyethylene, polystyrene, polytetrafluoroethylene, expanded polytetrafluoroethylene, polyvinyl chloride, polyamide, polyacrylate, polyurethane, polyvinyl alcohol, polyurethane, poly ethyl vinyl acetate, poly(butyl methacrylate), poly(ethylene-co-vinyl acetate), polycaprolactone, polylactide, polyglycolide and copolymers of any two or more of the foregoing; siloxanes such as 2,4,6,8-tetramethylcyclotetrasiloxane; natural and artificial rubbers; glass; and metals including stainless steel, titanium, platinum, and nitinol.
  • the binding of the HBGF analogs to the hydrophobic surface is of sufficient quantity to be detected by an analytical method such as an enzyme-linked immunoassay or a biological assay.
  • the Y region of formulas I to VI includes a chain of atoms or a combination of atoms that form a chain.
  • the chains are chains of carbon atoms, that may also optionally include oxygen, nitrogen or sulfur atoms, such as for example chains of atoms formed from amino acids (e.g. amino acids found in proteins, as listed above; naturally occurring amino acids not found in proteins, such as ornithine and citrulline; or non-natural amino acids, such as straight chain amino carboxylic acid; or a combination of any of the foregoing amino acids).
  • the chain of atoms of the Y region of formula I to VI is covalently attached to R 1 and to peptide Z.
  • the covalent bonds can be, for example, peptide, amide, thioether or ester bonds.
  • the Y region includes a chain of a minimum of about nine backbone atoms. More preferably, the Y region includes a chain of a minimum of about twelve atoms. Most preferably, the Y region includes a chain of a minimum of about fifteen atoms.
  • the Y region may be formed from a chain of at least four, at least five or at least six amino acids. Alternatively, the Y region may be formed from a chain of at least one, at least two, or at least three aminohexanoic acid residues.
  • the Y region includes a chain of a maximum of about fifty atoms. More preferably, the Y region includes a chain of a maximum of about forty-five atoms. Most preferably, the Y region includes a chain of a maximum of about thirty-five atoms.
  • the Y region may be formed from a chain of up to about twelve, up to about fifteen, or up to about seventeen amino acids.
  • the amino acid sequence of the Y region is preferably an artificial sequence, i.e. it does not include any amino acid sequence of four or more amino acid residues found in a natural ligand of a HBGF.
  • the Y region includes a hydrophobic amino acid residue, or a chain of hydrophobic amino acid residues.
  • the Y region can, for example, include one or more straight chain amino carboxylic acids, such as for example aminohexanoic acid residues, such as one, two, three or more aminohexanoic acid residues.
  • the Y region can include up to about twelve, up to about fifteen, or up to about seventeen ethylene glycol residues.
  • the Y region can include a combination of amino acid hydrophobic residues.
  • the Y region of the molecule can include a branched or unbranched, saturated or unsaturated alkyl chain of between one and about twenty carbon atoms.
  • the Y region can include a chain of hydrophilic residues, such as for instance, ethylene glycol residues.
  • the Y region can include at least about three, or at least about four, or at least about five ethylene glycol residues.
  • the Z region of the molecule of formula I is a heparin-binding region and can include one or more heparin-binding motifs, BBxB or BBBxxB as described by Verrecchio et al. J. Biol. Chem. 275:7701 (2000).
  • the Z region can include both BBxB and BBBxxB motifs (where B represents lysine, arginine, or histidine, and x represents a naturally occurring, or a non-naturally occurring amino acid).
  • the heparin-binding motifs may be represented by the sequence [KR][KR][KR]X(2)[KR] (SEQ ID NO:1), designating the first three amino acids as each independently selected from lysine or arginine, followed by any two amino acids and a sixth amino acid which is lysine or arginine.
  • the Z region may include at least one, at least two, at least three or at least five heparin-binding motifs. Where there are more than one heparin-binding motifs, the motifs may be the same or different.
  • the Z region includes up to a maximum of about ten heparin-binding motifs.
  • the Z region includes at least four, at least six or at least eight amino acid residues. Further, in certain embodiments the Z region includes up to about twenty, up to about, twenty-five, or up to about thirty amino acid residues.
  • the avidity of the Z region for heparin is determined by the particular heparin-binding motifs selected and the number of such motifs in Z.
  • both the selection and number of such motifs may be varied to provide optimal heparin binding of the Z region.
  • the amino acid sequence of the Z region is RKRKLERIAR (SEQ ID NO:2).
  • the amino acid sequence of the Z region is RKRKLGRIAR (SEQ ID NO:3).
  • the amino acid sequence of the Z region is RKRKLWRARA (SEQ ID NO:4).
  • the amino acid sequence of the Z region is RKRLDRIAR (SEQ ID NO:5), providing a heparin-binding motif derived from a modification of the sequence at residues 270-279 of the Jun/AP-1 DNA binding domain (Busch et al.
  • the amino acid sequence of the Z region is RKRKLERIARC (SEQ ID NO:6).
  • detection reagents such as fluorochromes, radioisotopes and other detectable markers, to the Z region, as well as the opportunity to link toxins, immunogens and the like.
  • Heparin-binding domains that bear little or no sequence homology to known heparin-binding domains are also contemplated in the present invention.
  • heparin-binding means binding to the —NHSO 3 ⁇ and sulfate modified polysaccharide, heparin, and also binding to the related modified polysaccharide, heparan.
  • Such domains are contemplated to exhibit binding in physiological solutions including 0.15 M NaCl, and are expected to uncomplex at salt concentrations greater than 0.5 M NaCl.
  • the Z region of the synthetic HBGF analogs of the present invention confers the property of binding to heparin in low salt concentrations, up to about 0.15 M NaCl, optionally up to about 0.48 M NaCl, forming a complex between heparin and the Z region of the factor analog.
  • the complex can be dissociated in 1 M NaCl to release the synthetic HBGF analog from the heparin complex.
  • the Z region is a non-signaling peptide. Accordingly, when used alone the Z region binds to heparin which can be bound to a receptor of a HBGF, but the binding of the Z region peptide alone does not initiate or block signaling by the receptor.
  • the C-terminus of the Z region may be blocked or free.
  • the C terminus of the Z region may be the free carboxyl group of the terminal amino acid, or alternatively, the C terminus of the Z region may be a blocked carboxyl group, such as for instance, an amide group.
  • alkene includes unsaturated hydrocarbons that contain one or more double carbon-carbon bonds. Examples of such alkene groups include ethylene, propene, and the like.
  • alkenyl includes a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms containing at least one double bond; examples thereof include ethenyl, 2-propenyl, and the like.
  • alkyl groups specified herein include those alkyl radicals of the designated length in either a straight or branched configuration.
  • alkyl radicals include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tertiary butyl, pentyl, isopentyl, hexyl, isohexyl, and the like.
  • aryl includes a monovalent or bicyclic aromatic hydrocarbon radical of 6 to 12 ring atoms, and optionally substituted independently with one or more substituents selected from alkyl, haloalkyl, cycloalkyl, alkoxy, alkythio, halo, nitro, acyl, cyano, amino, monosubstituted amino, disubstituted amino, hydroxy, carboxy, or alkoxy-carbonyl.
  • substituents selected from alkyl, haloalkyl, cycloalkyl, alkoxy, alkythio, halo, nitro, acyl, cyano, amino, monosubstituted amino, disubstituted amino, hydroxy, carboxy, or alkoxy-carbonyl.
  • Examples of an aryl group include phenyl, biphenyl, naphthyl, 1-naphthyl, and 2-naphthyl, derivatives thereof, and the like.
  • aralkyl includes a radical—R a R b where R a is an alkylene (a bivalent alkyl) group and R b is an aryl group as defined above.
  • R a is an alkylene (a bivalent alkyl) group and R b is an aryl group as defined above.
  • aralkyl groups include benzyl, phenylethyl, 3-(3-chlorophenyl)-2-methylpentyl, and the like.
  • aliphatic includes compounds with hydrocarbon chains, such as for example alkanes, alkenes, alkynes, and derivatives thereof.
  • acyl includes a group RCO—, where R is an organic group.
  • R is an organic group.
  • An example is the acetyl group CH 3 CO—.
  • a peptide or aliphatic moiety is “acylated” when an alkyl or substituted alkyl group as defined above is bonded through one or more carbonyl ⁇ -(C ⁇ O)- ⁇ groups.
  • a peptide is most usually acylated at the N-terminus.
  • An “amide” includes compounds that have a trivalent nitrogen attached to a carbonyl group (—CO.NH 2 ).
  • An “amine” includes compounds that contain an amino group (—NH 2 ).
  • a “diamine amino acid” is an amino acid or residue containing two reactive amine groups and a reactive carboxyl group. Representative examples include 2,3 diamino propionyl amino acid, 2,4 diamino butylic amino acid, lysine or ornithine.
  • homologous refers to peptides that differ in amino acid sequence at one or more amino acid positions when the sequences are aligned.
  • the amino acid sequences of two homologous peptides can differ only by one amino acid residue within the aligned amino acid sequences of five to ten amino acids.
  • two homologous peptides of ten to fifteen amino acids can differ by no more than two amino acid residues when aligned.
  • two homologous peptides of fifteen to twenty or more amino acids can differ by up to three amino acid residues when aligned.
  • homologous peptides can differ by up to approximately 5%, 10%, 20% or 25% of the amino acid residues when the amino acid sequences of the two peptide homologs are aligned.
  • a “trifunctional amino acid” is an amino acid or residue with three reactive groups, one the N-terminus amine, a second the C-terminus carboxyl, and the third comprising all or a part of the side chain.
  • Trifunctional amino acids thus include, by way of example only, diamine amino acids; amino acids with a reactive sulfhydryl group in the side chain, such as mercapto amino acids including cysteine, penicillamine, or 3-mercapto phenylalanine; amino acids with a reactive carboxyl group in the side chain, such as aspartic acid and glutamic acid; and amino acids with a reactive guanadium group in the side chain, such as arginine.
  • the invention provides a synthetic FGF peptide analog.
  • the X region of the molecule of formulas I to VI can include an amino acid sequences found in an FGF, such as for instance FGF-2 or FGF-7.
  • the X regions can include sequences not found in the natural ligand of the FGFR bound by the molecule.
  • the Y region of the synthetic FGF peptide analogs of any of formulas I to VI are not necessarily hydrophobic, and thus, if present, can be polar, basic, acidic, hydrophilic or hydrophobic.
  • the amino acid residues of the Y region of synthetic FGF peptide analogs can include any amino acid, or polar, ionic, hydrophobic or hydrophilic group.
  • the X region of synthetic FGF peptide analogs can include an amino acid sequence that is 100% identical to an amino acid sequence found in a fibroblast growth factor or an amino acid sequence homologous to the amino acid sequence of a fibroblast growth factor.
  • the X region can include an amino acid sequence that is at least about 50%, at least about 75%, or at least about 90% homologous to an amino acid sequence from a fibroblast growth factor.
  • the fibroblast growth factor can be any fibroblast growth factor, including any of the known or yet to be identified fibroblast growth factors.
  • the synthetic FGF analog of the invention is an agonist of the HBGFR.
  • the synthetic HBGF analog initiates a signal by the HBGFR.
  • the synthetic FGF analog of the invention is an antagonist of the HBGFR.
  • the synthetic HBGF analog blocks signaling by the HBGFR.
  • the synthetic FGF analog is an analog of FGF-2 (also known as basic FGF, or bFGF).
  • FGF-2 also known as basic FGF, or bFGF
  • the binding of the synthetic FGF analog to an FGF receptor initiates a signal by the FGF receptor.
  • the binding of the synthetic FGF analog to the FGF receptor blocks signaling by the FGF receptor.
  • the present invention provides a synthetic FGF analog of FGF-2.
  • the present invention provides a synthetic FGF analog of FGF-2, wherein the amino acid sequence of the X region is YRSRKYTSWYVALKR (SEQ ID NO:7) from FGF-2.
  • the present invention provides a synthetic FGF analog wherein the amino acid sequence of the X region is NRFHSWDCIKTWASDTFVLVCYDDGSEA (SEQ ID NO:8).
  • the present invention provides a synthetic FGF-2 analog wherein the amino acid sequence of the X region is HIKLQLQAEERGVVS (SEQ ID NO:9).
  • the invention provides a synthetic FGF analog of FGF-1, wherein the X region is YISKKHAEKNWFVGLKK (SEQ ID NO: 10). This sequence is derived from amino acids bridging the beta 9 and beta 10 loop of FGF-1.
  • an FGF-1 analog is provided wherein the X region is HIQLQLSAESVGEVY (SEQ ID NO:11), corresponding to amino acids derived from the ⁇ -4 and ⁇ -5 region of FGF-1.
  • the invention provides a synthetic FGF analog of FGF-7, wherein the X region is YASAKWTHNGGEMFVALNQK (SEQ ID NO:12).
  • the X region is the amino acid sequence YNIMEIRTVAVGIVA (SEQ ID NO:13).
  • FGF receptor binding domains derived largely from targeting sequences in the C-terminus of human FGF, include the following sequences shown in Table 1:
  • the invention provides a synthetic VEGF peptide analog.
  • the synthetic VEGF analogs represented include, in one embodiment, a VEGF analog wherein the amino acid sequence of the X region is APMAEGGGQNHHEVVKFMDV (SEQ ID NO:25).
  • a synthetic VEGF peptide analog wherein the amino acid sequence of the X region is GATWLPPNPTK (SEQ ID NO:26).
  • a synthetic VEGF peptide analog wherein the amino acid sequence of the X region is NFLLSWVHWSLALLLYLHHA (SEQ ID NO:27).
  • the invention provides a synthetic BMP peptide analog.
  • the synthetic bone morphogenic protein analogs include embodiments wherein the X region includes the amino acid sequence
  • LYVDFSDVGWNDW (SEQ ID NO:28) AISMLYLDENEKVVL, (SEQ ID NO:29) ISMLYLDENEKVVLKNY, (SEQ ID NO:30) EKVVLKNYQDMVVEG, (SEQ ID NO:31) LVVKENEDLYLMSIAC, (SEQ ID NO:32) AFYCHGECPFPLADHL, (SEQ ID NO:33) PFPLADHLNSTNHAIVQTLVNSV, (SEQ ID NO:34) TQLNAISVLYFDDSSNVILKKYRNMVV, (SEQ ID NO:87) and/or HELYVSFRDLGWQDWIIAPEGYAAY. (SEQ ID NO:88)
  • the invention provides synthetic Avinin A
  • the synthetic Avinin A protein analogs include embodiments wherein the X region includes the amino acid sequence SMLYYDDGQNIIKK (SEQ ID NO:89), KKIINQGDDYYLMS (SEQ ID NO:90), and/or SMLYYDDGQNIIKKDI (SEQ ID NO:91).
  • the synthetic G-CSF protein analogs include embodiments wherein the X region includes the amino acid sequence ASSLPQSFLLKCLEQVRKIQ (SEQ ID NO:92), LDVADFATTIWQQMEEL (SEQ ID NO:93), and/or YKLAHPEELVL (SEQ ID NO:94)
  • the synthetic GM-CSF protein analogs include embodiments wherein the X region includes the amino acid sequence WEHVNAIQEARRLLNL (SEQ ID NO:95), LQTRLELYKQGLRGSLTKLKGPLTMMASHYKQH (SEQ ID NO:96), and/or SFKENLKDFLLVI (SEQ ID NO:97)
  • the invention provides synthetic IFN-beta
  • the synthetic IFN-beta protein analogs include embodiments wherein the X region includes the amino acid sequence SVQARWEAAFDLDLY (SEQ ID NO:98), YLDLDFAAEWRAQVS (SEQ ID NO:99), and/or SSSTGWNETIVENLI (SEQ ID NO:100)
  • the synthetic PDGF protein analogs include embodiments wherein the X region includes the amino acid sequence KTRTEVFEISRRLIDRTNANFLVW (SEQ ID NO:101), and/or QVRKIEIVRKKPIFKK (SEQ ID NO:102)
  • the synthetic SDF-1 protein analogs include embodiments wherein the X region includes the amino acid sequence, KPVSLSYRCPCRFFESHVA (SEQ ID NO:103), and/or KWIQEYLEK (SEQ ID NO:104)
  • the invention provides synthetic BMP, TGF and GDF (growth differentiation factor) peptide analogs as shown in Table 2 wherein the transforming growth factor family member peptides are particularly useful in augmenting the activity of endogenous or artificial BMP peptides or TGF peptides, wherein is shown (under the heading “preferred receptor binding domain”) the sequence forming all or part of the X region of constructs of any of formulas I to VI.
  • GDF growth differentiation factor
  • the X region may be synthesized in a reverse direction, such that considering the sequence AISMLYLDENEKVVL (SEQ ID NO:29) illustrated in the conventional N ⁇ C orientation, and using formula II, the first amino acid bound to either the R 1 side chain or N-terminus amine is the N-terminus amino acid residue (bound through its carboxyl group thereby forming a peptide bond), the second amino acid bound to the N-terminus amino acid residue is the 2 position residue, and so on, and the compounds nonetheless retain biological activity and specifically bind to a BMP receptor.
  • such a construct has, based on a conventional N ⁇ C orientation, a reverse sequence, in that it is the carboxyl group of the conventional N-terminus amino acid residue that forms a peptide bond with an amine of R 1 where R 1 is a diamine amino acid.
  • the foregoing sequences may be employed in a reverse orientation, and the resulting compound of present invention is biologically active and may be employed as described herein.
  • the X region is the sequence LVVKENEDLYLMSIA (SEQ ID NO:57) (again considering the sequence in the conventional N ⁇ C orientation.
  • LVVKENEDLYLMSIA include but are not limited to YNKLVVKENEDLYLMSI (SEQ ID NO:58), KKLIVNSSEDFYL (SEQ ID NO:59), WDNWGVDSFDVYL (SEQ ID NO:60), GEVVMDQYNKLVVKE (SEQ ID NO:61), LHDALPFPCEGHCYFA (SEQ ID NO:62), VSNVLTQVIAHNTSNLHDALPFP (SEQ ID NO:63), and LVVKENEDLYLMSIAC (SEQ ID NO:64).
  • each of the R 2 regions of formula I are different, and in formulas IV and VI only one R 1 group is provided. Even in formula I it is contemplated that such regions may differ; for example, in formula I the R 1 may be a diamine amino acid, such as lysine. It is possible to utilize an orthogonal protecting group during synthesis to protect either the alpha amine or epsilon amine, to thereafter add one or amino acid residues or other groups to form an R 2 group, and then to remove the orthogonal protecting group, and proceed with parallel synthesis of the X groups from the deprotected amine on R 1 and the terminal amine on R 2 .
  • Methods of synthesizing the heparin-binding growth factor analogs can be achieved by any of a variety of chemical methods well known in the art. Such methods include bench scale solid phase synthesis and automated peptide synthesis in any one of the many commercially available peptide synthesizers. Preferably, the synthesizer has a per cycle coupling efficiency of greater than 99 percent.
  • the analogs of the present invention can be produced by stepwise synthesis or by synthesis of a series of fragments that can be coupled by similar well known techniques. See, for instance, Nyfeler, Peptide synthesis via fragment condensation. Methods Mol. Biol. 35:303-16 (1994); and Merrifield, Concept and early development of solid-phase peptide synthesis. Methods in Enzymol. 289:3-13 (1997). These methods are routinely used for the preparation of individual peptides. It is possible to assemble the analogs of the present invention in component parts, such as peptides constituting the X, Y and Z components thereof, and to thereafter couple such component parts to assemble the analog. See, for instance, Dawson and Kent, Synthesis of native proteins by chemical ligation. Annu. Rev.
  • the compounds of the present invention are synthesized by solid phase synthesis, with the C-terminus residue of the Z region of formulas I to VI bound to resin, and the synthesis proceeding stepwise.
  • Conventional protecting groups are employed as required, with deprotection either prior to, during or following cleavage of the peptide from the resin.
  • Peptide libraries that can be used to screen for a desired property, such as binding to an HBGFR can be prepared by adaptations of these methods. See for instance, Fox, Multiple peptide synthesis, Mol. Biotechnol. 3:249-58 (1995); and Wade and Tregear, Solid phase peptide synthesis: recent advances and applications. Austral. Biotechnol. 3:332-6 (1993).
  • the synthetic HBGF analog of the invention is an agonist of the HBGFR.
  • the synthetic HBGF analog initiates a signal by the HBGFR.
  • the synthetic HBGF analog of the invention is an antagonist of the HBGFR.
  • the synthetic HBGF analog blocks signaling by the HBGFR.
  • the invention provides a method for stimulating growth factor receptor signaling in a cell by contacting the cell with an effective amount of a synthetic HBGF analog according to formulas I to VI.
  • the effective amount can be readily determined by one of skill in the art.
  • the signaling can result in cytokine release from the cell, stimulation or inhibition of proliferation or differentiation of the cell, chemotaxis of the cell, stimulation or inhibition of the immune system of the mammal.
  • the HBGF analogs of the invention provide a cost effective and potentially unlimited source of biologically active molecules that are useful in a number of ways, including as soluble prophylactic or therapeutic pharmaceutical agents, such as for instance for administration as a soluble drug for prevention or treatment of various diseases, including for example, uses in cancer therapy and radioprotection.
  • the synthetic HBGF analogs of present invention are also useful as biologically active agents for coating of medical devices, such as for instance, sutures, implants and medical instruments to promote biological responses, for instance, to stimulate growth and proliferation of cells, or healing of wounds.
  • the present invention provides a method and compositions for treating a mammal that has been exposed to a harmful dose of radiation.
  • the method includes administering an effective dose of a synthetic HBGF analog of the invention which is an FGF analog to the mammal.
  • the treatment is particularly useful in the prevention or treatment of mucositis, gastrointestinal syndrome (G.I. syndrome), or radionecrosis such as can result from exposure to radiation.
  • the HBGF analog can be administered parenterally, orally, or topically. Alternatively, the HBGF analog can be delivered loco-regionally, e.g. on an analog coated medical device.
  • the present invention provides a method for treating a mammal that has been administered a dose of a chemotherapeutic agent, to ameliorate the toxicity of the chemotherapeutic agent to the mammal.
  • the mammal is a human.
  • the HBGF analog is an FGF-2 analog or an FGF-7 analog.
  • the invention provides a method and compositions for treating a mammal with bone injury, by providing a HBGF analog of the present invention having an X region reactive with a BMP HBGFR, such as an analog of BMP-2.
  • a BMP HBGFR such as an analog of BMP-2.
  • such HBGF analogs of the present invention may be administered as a pharmaceutical agent, or may be employed as an additive to bone matrix or bone graft materials.
  • the invention provides a method and compositions for preparation of cell or organ implant sites.
  • a homodimeric HBGF analog of FGF-2 of the present invention is administered by a percutaneous route to stimulate localized angiogenesis prior to implant of insulin-secreting pancreatic cells, and thereby improve the survival of the implanted cells.
  • a homodimeric HBGF analog of FGF-2 of the present invention is administered into ischemic heart tissue prior to the implant of myocte stem cells.
  • the invention provides a method and compositions to increase cellular attachment to and cellular retention on blood-contacting surfaces of medical devices.
  • a homodimeric HBGF analog of VEGF of the present invention is applied on vascular graft materials such that the bound analog recruits and binds circulating endothelial stem cells from the blood, thereby resulting in endothelialization of the graft surface with resultant long-term thromboresistance being imparted to the graft.
  • the invention provides a method and compositions to increase and provide for membrane-guided tissue growth.
  • the invention provides a method and composition for treatment of difficult-to-treat dermal wounds, including ulcers.
  • a homodimeric HBGF analog of TGF- ⁇ 1 is applied topically in a pharmaceutically acceptable cream or gel for treatment of ulcerated bed sores and similar difficult-to-treat dermal wounds.
  • the invention provides a method and compositions to selectively increase cellular populations in vitro.
  • a homodimeric HBGF analog of TGF- ⁇ 1 is formulated in a tissue culture medium to specifically stimulate the growth of chondrocytes, stem cells which give rise to chondrocytes, or pluripotent cells which give rise of chondrocytes.
  • a homodimeric HBGF analog of VEGF may be employed to stimulate the growth of endothelial cells.
  • medical device means a device that has one or more surfaces in contact with an organ, tissue, blood or other bodily fluid in an organism, preferably a mammal, particularly, a human.
  • Medical devices include, for example, extracorporeal devices for use in surgery such as blood oxygenators, blood pumps, blood sensors, tubing used to carry blood, and the like which contact blood that is returned to the patient.
  • the term can also include endoprostheses implanted in blood contact in a human or animal body, such as vascular grafts, stents, pacemaker leads, heart valves, and the like that are implanted in blood vessels or in the heart.
  • the term can further include devices for temporary intravascular use such as catheters, guide wires, and the like that are placed in blood vessels or the heart for purposes of monitoring or repair.
  • the term can further include nerve electrodes, muscle electrodes, implantable pulse generators, implantable drug pumps, and defibrillators.
  • the term medical device can include sutures, graft materials, wound coverings, nerve guides, bone wax, aneurysm coils, embolization particles, microbeads, dental implants, bone prostheses, tissue scaffolds, artificial joints or a controlled release drug delivery devices.
  • the surface of the medical device can be formed from any of the commonly used materials suitable for use in medical devices, such as for instance, stainless steel, titanium, platinum, tungsten, ceramics, polyurethane, polytetrafluoroethylene, extended polytetrafluoroethylene, polycarbonate, polyester, polypropylene, polyethylene, polystyrene, polyvinyl chloride, polyamide, polyacrylate, polyurethane, polyvinyl alcohol, polycaprolactone, polylactide, polyglycolide, polysiloxanes (such as 2,4,6,8-tetramethylcyclotetrasiloxane), natural rubbers, or artificial rubbers, or block polymers or copolymers thereof.
  • the invention provides a method for delivering an active peptide to a mammal, the method includes (i) providing a medical device coated on its surface with a synthetic HBGF analog of formulas I to VI, the synthetic HBGF analog being bound to the surface of the medical device by non-covalent bonds; and (ii) placing the medical device onto a surface of, or implanting the medical device into, the mammal.
  • the non-covalent bonds are associations between the heparin binding domain of the synthetic HBGF analog and a heparin-containing compound bound to the surface of the medical device.
  • the heparin-containing compound bound to the surface of the medical device can be any heparin-containing compound, such as for instance, benzyl-bis(dimethylsilylmethyl)oxy carbamoyl-heparin.
  • the medical device is not pre-coated with a heparin-containing compound before being coated with the synthetic HBGF analog of formulas I to VI.
  • the HBGF analogs of this invention can be used for as an active ingredient in pharmaceutical compositions for both medical applications and animal husbandry or veterinary applications. Typically, the HBGF analog or pharmaceutical composition is used in humans, but may also be used in other mammals.
  • the term “patient” is intended to denote a mammalian individual, and is so used throughout the specification and in the claims. The primary applications of this invention involve human patients, but this invention may be applied to laboratory, farm, zoo, wildlife, pet, sport or other animals.
  • the HBGF analogs of this invention may be in the form of any pharmaceutically acceptable salt.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, lithium, magnesium, potassium, and sodium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
  • basic ion exchange resins such as
  • acid addition salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, carboxylic, citric, ethanesulfonic, formic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, malonic, mucic, nitric, pamoic, pantothenic, phosphoric, propionic, succinic, sulfuric, tartaric, p-toluenesulfonic acid, trifluoroacetic acid, and the like.
  • Acid addition salts of the HBGF analogs of this invention are prepared in a suitable solvent for the HBGF analog and an excess of an acid, such as hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, trifluoroacetic, citric, tartaric, maleic, succinic or methanesulfonic acid.
  • an acid such as hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, trifluoroacetic, citric, tartaric, maleic, succinic or methanesulfonic acid.
  • suitable pharmaceutically acceptable salts may include alkali metal salts, such as sodium or potassium salts, or alkaline earth metal salts, such as calcium or magnesium salts.
  • the invention provides a pharmaceutical composition that includes a HBGF analog of this invention and a pharmaceutically acceptable carrier.
  • the carrier may be a liquid formulation, and in one embodiment a buffered, isotonic, aqueous solution.
  • Pharmaceutically acceptable carriers also include excipients, such as diluents, carriers and the like, and additives, such as stabilizing agents, preservatives, solubilizing agents, buffers and the like, as hereafter described.
  • HBGF analog compositions of this invention may be formulated or compounded into pharmaceutical compositions that include at least one HBGF analog of this invention together with one or more pharmaceutically acceptable carriers, including excipients, such as diluents, carriers and the like, and additives, such as stabilizing agents, preservatives, solubilizing agents, buffers and the like, as may be desired.
  • pharmaceutically acceptable carriers including excipients, such as diluents, carriers and the like, and additives, such as stabilizing agents, preservatives, solubilizing agents, buffers and the like, as may be desired.
  • Formulation excipients may include polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, PEG, PEO, mannitol, sodium chloride or sodium citrate, as well as any number of simple sugars, including sucrose, dextrose, lactose and the like, and combinations of the foregoing.
  • water containing at least one or more buffering constituents is preferred, and stabilizing agents, preservatives and solubilizing agents may also be employed.
  • stabilizing agents, preservatives and solubilizing agents may also be employed.
  • solid administration formulations any of a variety of thickening, filler, bulking and carrier additives may be employed, such as starches, sugars, fatty acids and the like.
  • topical administration formulations any of a variety of creams, ointments, gels, lotions and the like may be employed.
  • non-active ingredients will constitute the greater part, by weight or volume, of the preparation.
  • any of a variety of measured-release, slow-release or time-release formulations and additives may be employed, so that the dosage may be formulated so as to effect delivery of a HBGF analog of this invention over a period of time.
  • the HBGF analogs of the invention can be combined as the active ingredient in an admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, for example, oral, parenteral (including intravenous), urethral, vaginal, nasal, buccal, sublingual, or the like.
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets.
  • oral liquid preparations such as, for example, suspensions, elixirs and solutions
  • carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that it may be administered by syringe.
  • the form must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a polyol, for example glycerol, propylene glycol or liquid polyethylene glycol, suitable mixtures thereof, and vegetable oils.
  • the injection may be intravenous, subcutaneous, intramuscular, intraperitoneal or other means known in the art.
  • the HBGF analogs of this invention may alternatively be formulated by any means known in the art, including but not limited to formulation as tablets, capsules, caplets, suspensions, powders, lyophilized preparations, suppositories, ocular drops, skin patches, oral soluble formulations, sprays, aerosols and the like, and may be mixed and formulated with buffers, binders, excipients, stabilizers, anti-oxidants and other agents known in the art.
  • any route of administration by which the HBGF analogs of invention are introduced across an epidermal layer of cells may be employed.
  • Administration means may thus include administration through mucous membranes, buccal administration, oral administration, dermal administration, inhalation administration, nasal administration, urethral administration, vaginal administration, and the like.
  • the actual quantity of HBGF analog of this invention administered to a patient will vary between fairly wide ranges depending upon the mode of administration, the formulation used, and the response desired.
  • the dosage for treatment is administration, by any of the foregoing means or any other means known in the art, of an amount sufficient to bring about the desired therapeutic effect.
  • Heparin-binding growth factors The fibroblast growth factors, FGFs, constitute a family of related proteins controlling normal growth and differentiation of mesenchymal, epithelial, and neuroectodermal cell types. Homologs have been found in a wide variety of species. FGFs show a very high affinity to heparin and are therefore also referred to as heparin-binding growth factors (HBGFs). As used herein, the term HBGFs includes all FGFs.
  • FGF FGF-2 heparin-binding growth factor-2
  • FGF acidic FGF
  • HBGF-1 heparin-binding growth factor-1
  • HBGF- ⁇ heparin-binding growth factor- ⁇
  • fibroblast growth factors belonging to the same family include FGF-3 (or HBGF-3, heparin-binding growth factor-3, originally called int-2; see Fekete, Trends in Neurosci. 23:332 (2000)), FGF-4 (HBGF4, heparin-binding growth factor-4, initially recognized as the product of the oncogene hst; see Sakamoto et al., Proc. Natl. Acad. Sci. USA 91:12368-72), and FGF-5 (originally called HBGF-5, see Bates et al. Biosynthesis of human fibroblast growth factor 5. Mol. Cell. Biol.
  • FGF-6 is also known as HBGF-6, and sometimes called hst-2 or oncogene hst-1 related growth factor, see Iida et al. Human hst-2 (FGF-6) oncogene: cDNA cloning and characterization. Oncogene 7:303-9 (1992); and Marics et al. Characterization of the HST-related FGF-6 gene, a new member of the fibroblast growth factor gene family. Oncogene 4:335-40 (1989).
  • FGF-7 or K-FGF is also known as KGF or keratinocyte growth factor (See Aaronson et al. Keratinocyte growth factor. A fibroblast growth factor family member with unusual target cell specificity. Annals NY Acad. Sci. 638:62-77 (1991)); Finch et al. Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science 245:752-5 (1989); Marchese et al. Human keratinocyte growth factor activity on proliferation and differentiation of human keratinocytes: differentiation response distinguishes KGF from EGF family. J. Cellular Physiol. 144: 326-32 (1990)).
  • FGF-8 was found to be identical to androgen-induced growth factor, AIGF and has been well studied (See Blunt et al. Overlapping expression and redundant activation of mesenchymal fibroblast growth factor (FGF) receptors by alternatively spliced FGF-8 ligands. J. Biol. Chem. 272:3733-8 (1997)); Dubrulle et al. FGF signaling controls somite boundary position and regulates segmentation clock control of spatiotemporal Hox gene activation. Cell 106:219-232 (2001); Gemel et al. Structure and sequence of human FGF8. Genomics 35:253-257 (1996); Tanaka et al. A novel isoform of human fibroblast growth factor 8 is induced by androgens and associated with progression of esophageal carcinoma. Dig. Dis. Sci. 46:1016-21 (2001)).
  • FGF-9 was originally called glia activating factor, or HBGF-9. See Miyamoto et al. Molecular cloning of a novel cytokine cDNA encoding the ninth member of the fibroblast growth factor family, which has a unique secretion pattern. Mol. Cell. Biol. 13:4251-9 (1993); and Naruo et al. Novel secretory heparin-binding factors from human glioma cells (glia-activating factors) involved in glial cell growth. J. Biol. Chem. 268: 2857-64 (1993).
  • FGF-10 is also called KGF-2, keratinocyte growth factor-2 (see Kok et al. Cloning and characterization of a cDNA encoding a novel fibroblast growth factor preferentially expressed in human heart. Biochem. Biophys. Res. Comm. 255:717-721, (1999)).
  • FGF-related factors have been described as fibroblast growth factor homologous factors (FHFs) and are also referred to as FGF-11 (FHF-3), FGF-12 (FHF-1), FGF-13 (FHF-2, see Greene et al. Identification and characterization of a novel member of the fibroblast growth factor family. Eur. J. Neurosci. 10:1911-1925 (1998)), and FGF-14 (FHF4).
  • FHFs fibroblast growth factor homologous factors
  • FHF-1 FGF-12
  • FGF-13 FGF-13
  • FGF-15 is expressed in the developing nervous system and was identified as a gene regulated by transcription factor E2A-Pbx1. McWhirter et al. A novel fibroblast growth factor gene expressed in the developing nervous system is a downstream target of the chimeric homeodomain oncoprotein E2A-Pbx1. Development 124:3221-3232 (1997).
  • FGF-16 was isolated as a cDNA clone from rat heart by homology-based polymerase chain reaction expressing an FGF of 207 amino acids. FGF-16 is 73% identical to FGF-9. Miyake et al. Structure and expression of a novel member, FGF-16, of the fibroblast growth factor family. Biochem. Biophys. Res. Commun. 243:148-152 (1998).
  • the cDNA encoding FGF-17 was isolated from rat embryos and encodes a protein of 216 amino acids. When expressed in 3T3 fibroblasts, mouse FGF-17 is transforming. During embryogenesis, FGF-17 is expressed at specific sites in forebrain, the midbrain-hindbrain junction, the developing skeleton and in developing arteries. See Hoshikawa et al. Structure and expression of a novel fibroblast growth factor, FGF-17, preferentially expressed in the embryonic brain. Biochem. Biophys. Res. Commun. 244:187-191 (1998); and Xu et al. Genomic structure, mapping, activity and expression of fibroblast growth factor 17. Mechanisms of Development 83:165-178 (1999).
  • the cDNA encoding FGF- 18 was isolated from rat embryos encoding a protein of 207 amino acids.
  • FGF-18 is a glycosylated protein and is most similar to FGF-8 and FGF-17.
  • Injection of recombinant murine FGF-18 has been shown to induce proliferation in tissues of both epithelial and mesenchymal origin, particularly in liver and small intestine.
  • Recombinant rat FGF-18 induces neurite outgrowth in PC12 cells.
  • Recombinant murine FGF- 18 protein stimulates proliferation in NIH 3T3 fibroblasts in vitro in a heparan sulfate-dependent manner.
  • FGF-18 a novel member of the fibroblast growth factor family, stimulates hepatic and intestinal proliferation. Mol. Cell. Biol. 18:6063-6074 (1998); and Ohbayashi et al. Structure and expression of the mRNA encoding a novel fibroblast growth factor, FGF-18. J. Biol. Chem. 273:18161-18164 (1998).
  • FGF-19 is related distantly to other members of the FGF family. FGF-19 mRNA is expressed in several tissues including fetal cartilage, skin, and retina, as well as adult gall bladder. It is overexpressed in a colon adenocarcinoma cell line. FGF-19 is a high affinity, heparin-dependent ligand for the FGF-4 receptor. See Xie et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4 Cytokine 11:729-735 (1999).
  • FGF-20 is expressed in normal brain, particularly the cerebellum, and in some cancer cell lines. FGF-20 mRNA is expressed preferentially in the substantia nigra pars compacta. Recombinant FGF-20 protein induces DNA synthesis in a variety of cell types and is recognized by multiple FGF receptors. FGF-20 functions like an oncogene, causing a transformed phenotype when expressed in the 3T3 fibroblast cell line. These transformed cells are tumorigenic in nude mice. See Jeffers et al. Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis. Cancer Res. 61:3131-8 (2001); and Ohmachi et al. FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. Biochem. Biophys. Res. Commun. 277:355-60 (2000).
  • FGF-21 was isolated from mouse embryos. FGF-21mRNA is most abundant in the liver with lower levels in the thymus. FGF-21 is most similar to human FGF-19. See Nishimura et al. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 1492:203-6 (2000).
  • FGF-22 (170 amino acids) was isolated from human placenta. FGF-22 is most similar to FGF-10 and FGF-7. Murine FGF-22 mRNA is expressed preferentially in the skin. FGF-22 mRNA in the skin is found preferentially in the inner root sheath of the hair follicle. See Nakatake et al. Identification of a novel fibroblast growth factor, FGF-22, preferentially expressed in the inner root sheath of the hair follicle. Biochim. Biophys. Acta 1517:460-3 (2001).
  • FGF-23 is most similar to FGF-21 and FGF-19.
  • the human FGF-23 gene maps to chromosome 12p13 linked to human FGF-6 gene.
  • FGF-23 mRNA is expressed mainly in the brain (preferentially in the ventrolateral thalamic nucleus) and thymus at low levels. Missense mutations in the FGF-23 gene have been found in patients with autosomal dominant hypophosphataemic rickets.
  • Overproduction of FGF23 causes tumor-induced osteomalacia, a paraneoplastic disease characterized by hypophosphatemia caused by renal phosphate wasting. See Yamashita et al.
  • FGF-23 a novel fibroblast growth factor, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 277:494-8 (2000); and Shimada et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. (USA) 98:6500-5 (2001).
  • HBBM Heparin-binding brain mitogen
  • HB-GAF heparin-binding growth associated factor
  • HBNF heparin-binding neurite-promoting factor
  • HB-EGF heparin-binding EGF-like factor
  • HB-EGF heparin-binding EGF-like factor
  • HB-EGF is a monomeric heparin-binding O-glycosylated protein of 86 amino acids and is processed from a precursor of 208 amino acids.
  • Several truncated forms of HB-EGF have been described.
  • HB-EGF is a potent mitogen for NIH 3T3 cells, keratinocytes and smooth muscle cells, but not for endothelial cells. The mitogenic activity on smooth muscle cells is much stronger than for EGF and appears to involve interactions with cell surface heparan sulfate proteoglycans.
  • HB-EGF is a major growth factor component of wound fluid and may play an important role in wound healing.
  • Heparin-binding EGF-like growth factor characterization of rat and mouse cDNA clones, protein domain conservation across species, and transcript expression in tissues. Biochem. Biophys. Res. Commun. 190:125-133 (1993); Higashiyama et al. A heparin-binding growth factor secreted by macrophage like cells that is related to EGF. Science 251:936-9 (1991); and Marikovsky et al. Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc. Natl. Acad. Sci. (USA) 90:3889-93.
  • HB-GAM heparin-binding growth associated molecule
  • HBNF heparin-binding neurite promoting factor
  • HB-GAM heparin-binding growth associated molecule
  • HBNF heparin-binding neurite promoting factor
  • TGF-beta exists in at least five isoforms, known TGF- ⁇ 1, TGF- ⁇ 2, TGF- ⁇ 3, TGF- ⁇ 4 and TGF- ⁇ 5, that are not related to TGF- ⁇ . Their amino acid sequences display homologies on the order of 70-80 percent. TGF- ⁇ 1 is the prevalent form and is found almost ubiquitously while the other isoforms are expressed in a more limited spectrum of cells and tissues.
  • TGF-beta is the prototype of a family of proteins known as the TGF-beta superfamily. This family includes inhibins, Activin A, MIS (Mullerian activating substance) and BMPs (Bone morphogenic proteins). Burt, Evolutionary grouping of the transforming growth factor-beta superfamily. Biochem. Biophys. Res. Commun. 184:590-5 (1992).
  • a compound of the present invention was synthesized by solid phase peptide chemistry with the general structure of formula I wherein X is a BMP-2 receptor binding amino acid sequence having the sequence AISMLYLDEKVVL(SEQ ID NO:105) wherein the sequence was grown in parallel from the R 1 trifunctional amino acid of formula I when R 2 is 0 atoms and R 1 is lysine.
  • the resulting synthetic growth modulator analog is of the following specific structure:
  • Ahx is 6-amino hexanoic acid, sometimes also called “6-Ahx” or “Hex”.
  • the single letters are standard amino acid single letter abbreviations for the naturally coded amino acids.
  • a compound of the present invention was synthesized by solid phase peptide chemistry with the general structure of formula I wherein X is a BMP receptor binding amino acid sequence having the sequence LYFDESSNVILKK(SEQ ID NO:106) which was grown in parallel from the R 1 trifunctional amino acid of formula I when R 2 is 0 atoms and R 1 is a lysine.
  • the resulting synthetic growth modulator analog is of the following specific structure:
  • Ahx is 6-amino hexanoic acid, sometimes also called “6-Ahx” or “Hex”.
  • the single letters are standard amino acid single letter abbreviations for the naturally coded amino acids.
  • a compound of the present invention is synthesized by solid phase peptide chemistry with the general structure of formula I wherein X is a BMP-2 receptor binding amino acid sequence having the sequence ISMLYLDENEKVVLKNY(SEQ ID NO:30) grown in parallel from an R 1 trifunctional amino acid of formula I and wherein R 1 is lysine.
  • the resulting synthetic growth modulator analog is of the following specific structure:
  • “Ahx” is 6-amino hexanoic acid, sometimes also called “6-Ahx” or “Hex”.
  • the single letters are standard amino acid single letter abbreviations for the naturally coded amino acids.
  • the synthetic FGF analog YRSRKYSSWYVALKRK(H-YRSRKYSSWYVALKR)-Ahx-Ahx-Ahx-RKRKLDRIAR-NH 2 was synthesized by standard solid phase peptide synthesis methods.
  • the R 1 group of formula I was a single trifunctional amino acid residue, here a diamine amino acid, lysine (K).
  • the peptide of Example 4 has an estimated molecular weight of 5681.
  • the peptide of Example 4 was assembled stepwise by solid-phase synthesis on a substituted resin, using Fmoc chemistry for temporary protection of amino groups in the repetitive cycles. Protecting groups were used as required. Branching of the chain was accomplished by stepwise growth of identical chains from the alpha amino group and side-chain amino group of a single lysyl residue. The completed peptide chain was cleaved from the resin as C-terminal amides by acidolysis, which also removed the acid-labile side-chain protecting groups.
  • the peptide of Example 4 was purified by reverse phase HPLC using a C 18 column in a continuous gradient elution of 0-60% B over 60 minutes, run at 1 mL/min, where A was 0.1% trifluoroacetate in water and B was 0.1% trifluoroacetate in acetonitrile.
  • the general structure of the compound of Example 4 is shown below:
  • a peptide was synthesized as a candidate agonist of PDGF-BB and designated PBA2-1C.
  • the peptide was branched from a single lysine (K) at the R 1 position, where the N-terminus residue of the branched sequence CVRKIEIVRKK(SEQ ID NO:107) was a cysteine (C) residue.
  • the resulting construct was a cyclic peptide, with the two X regions joined by a disulfide bond at the N-terminus cysteine.
  • the peptide was was purified by RP-HPLC on a C18 column, using a linear gradient 0-60% acetonitrile/water (0.1% trifluoroacetic acid) run over 60 min at 1 ml/min flow rate (detection at 214 nm).
  • the purified peptide generated a single uniform peak on analysis by RP-HPLC as indicated in FIG. 6 .
  • SPR Surface Plasmon Resonance
  • FIG. 7 illustrates the effect of peptide PBA2-1 on cell proliferation. Data is reported as the average ⁇ SD.
  • Any suitable carboxy protecting group is employed, if desired, on the second cysteine employed forming a disulfide bridge with the cysteine at the R 1 position. Synthesis may proceed without a protecting group, but for most synthetic methods it is desirable to employ a protecting group. The protecting group may be removed following synthesis, or alternatively may be left in place.
  • an ester is employed as a C-terminal protecting group, such as methyl, ethyl, benzyl or substituted benzyl esters. Other esters may be employed, including allyl esters or t-butyl esters.
  • SD1-1 A mimetic of SDF-1, the peptide designated SD1-1, was synthesized following standard Fmoc protocols using a NovaSyn TGR resin (EMD BioSciences, La Jolla, Calif.). Fmoc-amino acids including aminohexanoic acid (Ahx) were obtained from Peptides International, Inc. (Lexington, Ky.). SD1-1 has the following sequence:
  • SDF-1 was purified by RP-HPLC on a C18 column, using a linear gradient 0-60% acetonitrile/water (0.1% trifluoroacetic acid) run over 60 min at 1 ml/min flow rate (detection at 214 nm).
  • the purified peptide generated a single uniform peak on analysis by RP-HPLC as indicated in FIG. 1 .
  • Sup-T1 cells were obtained from the American Type Culture Collection (Manassas, Va.) and were grown in culture. To monitor the effect of SD1-1 on cell proliferation, Sup-T1 cells were seeded at 100,000 cells per well of a 96-well plate and allowed to attach. The medium was changed to one containing low serum plus SD1-1 and the cells incubated for 3 days after which time the relative cell number was determined using a commercially available kit Referring now to FIG. 2 , data in the graph below is reported as the average ⁇ SD. Commercially-available recombinant human SDF-1 (diamond) was used as a reference and positive control for comparison of proliferation stimulated by SDF-1 (triangle).
  • SD1-1 was evaluated for its abilty to induce migration of C2C12 cells using a commercially-avialable cell migration assay.
  • C2C12 cells were seeded on a trans-well insert containing an 8 ⁇ m pore size polycarbonate membrane coated with a thin layer of polymerized collagen. The inserts were placed into wells with medium containing SD1-1. Cells that migrated through the membrane were found on the bottom of the insert membrane. These cells were stained, and the stain extracted and detected on a standard microplate reader (560 nm).
  • FIG. 3 the results of cell migration in response to the SD1-1 peptide as compared to SDF-1 peptide or control are illustrated. Data is reported as the average ⁇ SD.
  • PBA2-1 A mimetic of PDGF, the peptide designated PBA2-1, was synthesized following standard Fmoc protocols using a NovaSyn TGR resin (EMD BioSciences, La Jolla, Calif.). Fmoc-amino acids including aminohexanoic acid (Ahx) were obtained from Peptides International, Inc. (Lexington, Ky.). PBA2-1 has the following sequence:
  • PBA2-1 was purified by RP-HPLC on a C18 column, using a linear gradient 0-60% acetonitrile/water (0.1% trifluoroacetic acid) run over 60 min at 1 mil/min flow rate (detection at 214 nm).
  • the purified peptide generated a single uniform peak on analysis by RP-HPLC as is illustrated in FIG. 4 .
  • SPR Surface Plasmon Resonance
  • FIG. 5 illustrates the effect of peptide PBA2-1 on cell proliferation over a concentration range of PBA2-1 peptide. Data is reported as the average ⁇ SD.
  • a peptide was synthesized based on a sequence of BMP-7.
  • the peptide was designated B7A1-6 and had the sequence:
  • This peptide was evaluated using C2C12 cells and in the presence of recombinant BMP-7 and using alkaline phosphatase production as an endpoint.
  • Alkaline phosphatase assays were performed using mouse the pluripotent cell lines C2C12. Cells were plated in 96-well (1 ⁇ 104/well) plates and allowed 24 hours to attach. The medium was then replaced with a serum low medium containing BMP-7 and/or B7A1-6. After several days, cells were rinsed, lysed, and alkaline phosphatase activity measured using p-nitrophenylphosphate as substrate. B7A1-6 had a dose-dependant suppression of the activity of BMP-7 as indicated in FIG. 8 .
  • GCSF1 A peptide was synthesized based on a sequence from G-CSF and designated GCSF1.
  • GCSF1 had the sequence:
  • SFLLKALEQVRKIQYK(SFLLKALEQVRKIQY)HxHxHxRKRKLERIAR- amide This peptide was evaluated for augmentation of growth using M-NSF-60 cells in the presence of 0.01 ng rhGCSF. As shown in FIG. 9 , the peptide augmented cellular growth as monitored using a commercially-available MTX kit.
US11/359,173 2004-02-10 2006-02-21 Single branch heparin-binding growth factor analogs Abandoned US20080227696A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US11/359,173 US20080227696A1 (en) 2005-02-22 2006-02-21 Single branch heparin-binding growth factor analogs
AU2006216676A AU2006216676A1 (en) 2005-02-22 2006-02-22 Single branch heparin-binding growth factor analogs
EP06735882A EP1855706A4 (en) 2005-02-22 2006-02-22 UNIQUE HEPARIN BINDING GROWTH FACTOR ANALOGUE
CA002598688A CA2598688A1 (en) 2005-02-22 2006-02-22 Single branch heparin-binding growth factor analogs
JP2007556427A JP4897708B2 (ja) 2005-02-22 2006-02-22 単一分岐ヘパリン結合増殖因子類似体
PCT/US2006/006397 WO2006091727A2 (en) 2005-02-22 2006-02-22 Single branch heparin-binding growth factor analogs
US11/361,090 US7671012B2 (en) 2004-02-10 2006-02-23 Formulations and methods for delivery of growth factor analogs
US12/786,256 US8101570B2 (en) 2005-02-22 2010-05-24 Single branch heparin-binding growth factor analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65557005P 2005-02-22 2005-02-22
US11/359,173 US20080227696A1 (en) 2005-02-22 2006-02-21 Single branch heparin-binding growth factor analogs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/167,636 Continuation-In-Part US20060024347A1 (en) 2004-02-10 2005-06-27 Bioactive peptide coatings

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/361,090 Continuation-In-Part US7671012B2 (en) 2004-02-10 2006-02-23 Formulations and methods for delivery of growth factor analogs
US12/786,256 Continuation US8101570B2 (en) 2005-02-22 2010-05-24 Single branch heparin-binding growth factor analogs

Publications (1)

Publication Number Publication Date
US20080227696A1 true US20080227696A1 (en) 2008-09-18

Family

ID=36928004

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/359,173 Abandoned US20080227696A1 (en) 2004-02-10 2006-02-21 Single branch heparin-binding growth factor analogs
US12/786,256 Expired - Fee Related US8101570B2 (en) 2005-02-22 2010-05-24 Single branch heparin-binding growth factor analogs

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/786,256 Expired - Fee Related US8101570B2 (en) 2005-02-22 2010-05-24 Single branch heparin-binding growth factor analogs

Country Status (6)

Country Link
US (2) US20080227696A1 (US20080227696A1-20080918-C00010.png)
EP (1) EP1855706A4 (US20080227696A1-20080918-C00010.png)
JP (1) JP4897708B2 (US20080227696A1-20080918-C00010.png)
AU (1) AU2006216676A1 (US20080227696A1-20080918-C00010.png)
CA (1) CA2598688A1 (US20080227696A1-20080918-C00010.png)
WO (1) WO2006091727A2 (US20080227696A1-20080918-C00010.png)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087505A1 (en) * 2002-08-20 2004-05-06 Pena Louis A. Synthetic heparin-binding factor analogs
US20060199764A1 (en) * 2002-08-20 2006-09-07 Biosurface Engineering Technologies, Inc. FGF growth factor analogs
US20080160169A1 (en) * 2006-06-22 2008-07-03 Zamora Paul O Coating device and method for coating medical device with bioactive peptide
US20080166392A1 (en) * 2002-08-20 2008-07-10 Zamora Paul O Positive Modulator of Bone Morphogenic Protein-2
US7820172B1 (en) * 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
US8101570B2 (en) 2005-02-22 2012-01-24 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US8163717B2 (en) 2002-08-20 2012-04-24 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US20160024170A1 (en) * 2006-11-13 2016-01-28 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
CN111936157A (zh) * 2018-02-13 2020-11-13 佛罗里达大学研究基金会 成纤维细胞生长因子类似物及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013201291B2 (en) * 2005-08-05 2015-08-13 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
KR20180067735A (ko) 2005-08-05 2018-06-20 아라임 파마슈티칼즈, 인크. 조직 보호 펩티드 및 이의 용도
NZ587105A (en) 2008-01-22 2012-09-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CN111303271B (zh) * 2020-02-19 2022-02-01 西安交通大学医学院第一附属医院 一种用于治疗肺纤维化的血小板源性生长因子重组疫苗及其应用
WO2022204331A1 (en) * 2021-03-24 2022-09-29 Combangio, Inc. Compositions comprising branched kgf-2 derived peptides and methods for use in ocular treatment
WO2024050602A1 (en) * 2022-09-09 2024-03-14 The University Of Sydney Novel platelet derived growth factor peptide mimetic

Citations (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3272204A (en) * 1965-09-22 1966-09-13 Ethicon Inc Absorbable collagen prosthetic implant with non-absorbable reinforcing strands
US4193138A (en) * 1976-08-20 1980-03-18 Sumitomo Electric Industries, Ltd. Composite structure vascular prostheses
US4747848A (en) * 1984-11-30 1988-05-31 Vascutek Limited Vascular grafts
US4842575A (en) * 1984-01-30 1989-06-27 Meadox Medicals, Inc. Method for forming impregnated synthetic vascular grafts
US5108436A (en) * 1988-09-29 1992-04-28 Collagen Corporation Implant fixation
US5197977A (en) * 1984-01-30 1993-03-30 Meadox Medicals, Inc. Drug delivery collagen-impregnated synthetic vascular graft
US5509899A (en) * 1994-09-22 1996-04-23 Boston Scientific Corp. Medical device with lubricious coating
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5650234A (en) * 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5665114A (en) * 1994-08-12 1997-09-09 Meadox Medicals, Inc. Tubular expanded polytetrafluoroethylene implantable prostheses
US5830995A (en) * 1988-01-25 1998-11-03 Bristol-Myers Squibb Company Fanphiregulins: a family of heparin-binding epithelial cell growth factors
US5916585A (en) * 1996-06-03 1999-06-29 Gore Enterprise Holdings, Inc. Materials and method for the immobilization of bioactive species onto biodegradable polymers
US5945457A (en) * 1997-10-01 1999-08-31 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science Process for preparing biologically compatible polymers and their use in medical devices
US6096798A (en) * 1996-04-30 2000-08-01 Luthra; Ajay Kumar Non-thrombogenic and anti-thrombogenic polymers
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6120904A (en) * 1995-02-01 2000-09-19 Schneider (Usa) Inc. Medical device coated with interpenetrating network of hydrogel polymers
US6231892B1 (en) * 1990-10-15 2001-05-15 The Board Of Regents, The University Of Texas System Compositions for coating microcapsules and other surfaces
US6231600B1 (en) * 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US6248057B1 (en) * 1998-07-28 2001-06-19 Innerdyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
US6258371B1 (en) * 1998-04-03 2001-07-10 Medtronic Inc Method for making biocompatible medical article
US20010014662A1 (en) * 1997-03-20 2001-08-16 David C Rueger Improved osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
US6306165B1 (en) * 1996-09-13 2001-10-23 Meadox Medicals ePTFE small caliber vascular grafts with significant patency enhancement via a surface coating which contains covalently bonded heparin
US6309660B1 (en) * 1999-07-28 2001-10-30 Edwards Lifesciences Corp. Universal biocompatible coating platform for medical devices
US6368347B1 (en) * 1999-04-23 2002-04-09 Sulzer Vascutek Ltd. Expanded polytetrafluoroethylene vascular graft with coating
US6387978B2 (en) * 1996-07-11 2002-05-14 Boston Scientific Corporation Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties
US6410044B1 (en) * 1998-03-19 2002-06-25 Surmodics, Inc. Crosslinkable macromers
US6426332B1 (en) * 1997-02-07 2002-07-30 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
US20020115836A1 (en) * 1998-09-22 2002-08-22 Ray Tsang Non-thrombogenic coating composition and methods for using same
US6458889B1 (en) * 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US20020160098A1 (en) * 1998-09-22 2002-10-31 Zamora Paul O. Nucleic acid coating compositions and methods
US6491965B1 (en) * 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6497729B1 (en) * 1998-11-20 2002-12-24 The University Of Connecticut Implant coating for control of tissue/implant interactions
US6514534B1 (en) * 1998-08-14 2003-02-04 Incept Llc Methods for forming regional tissue adherent barriers and drug delivery systems
US6534591B2 (en) * 1995-12-18 2003-03-18 Cohesion Technologies, Inc. Cross-linked polymer compositions and methods for their use
US6548634B1 (en) * 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6585765B1 (en) * 2000-06-29 2003-07-01 Advanced Cardiovascular Systems, Inc. Implantable device having substances impregnated therein and a method of impregnating the same
US20040038348A1 (en) * 2002-08-20 2004-02-26 Pena Louis A. Synthetic heparin-binding growth factor analogs
US20040151764A1 (en) * 2001-07-31 2004-08-05 Biosurface Engineering Technologies, Inc. Bioactive medical films
US6818018B1 (en) * 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6846853B2 (en) * 1999-12-28 2005-01-25 Osteotech, Inc. Calcium phosphate bone graft material, process for making same and osteoimplant fabricated from same
US6863899B2 (en) * 1999-08-13 2005-03-08 Vita Special Purpose Corporation Composite shaped bodies and methods for their production and use
US20050151764A1 (en) * 2004-01-08 2005-07-14 Eastman Kodak Company Liquid level detection method and apparatus
US6921811B2 (en) * 1998-09-22 2005-07-26 Biosurface Engineering Technologies, Inc. Bioactive coating composition and methods
US20050196425A1 (en) * 2002-08-20 2005-09-08 Biosurface Engineering Technologies, Inc. Positive modulator of bone morphogenic protein-2
US6949251B2 (en) * 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
US20050222394A1 (en) * 2002-08-20 2005-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US6984393B2 (en) * 2001-05-07 2006-01-10 Queen's University At Kingston Biodegradable elastomer and method of preparing same
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US20060063622A1 (en) * 2004-09-17 2006-03-23 Adidas International Marketing B.V. Bladder
US20060199764A1 (en) * 2002-08-20 2006-09-07 Biosurface Engineering Technologies, Inc. FGF growth factor analogs
US7241736B2 (en) * 2003-11-10 2007-07-10 Angiotech International Ag Compositions and methods for treating diverticular disease
US20080160169A1 (en) * 2006-06-22 2008-07-03 Zamora Paul O Coating device and method for coating medical device with bioactive peptide
US7414028B1 (en) * 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US7468210B1 (en) * 2002-12-10 2008-12-23 Biosurface Engineering Technologies, Inc. Cross-linked heparin coatings and methods
US20090111743A1 (en) * 2005-02-25 2009-04-30 Biosurface Engineering Technologies, Inc. Cysteine-branched heparin-binding growth factor analogs
US7528105B1 (en) * 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172128A (en) 1975-03-26 1979-10-23 Erhard Thiele Process of degrading and regenerating bone and tooth material and products
US4563350A (en) * 1984-10-24 1986-01-07 Collagen Corporation Inductive collagen based bone repair preparations
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US6919308B2 (en) 1988-04-08 2005-07-19 Stryker Corporation Osteogenic devices
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
US5576288A (en) 1989-04-27 1996-11-19 The Salk Institute For Biological Studies Fibroblast growth factor conjugates
US5759515A (en) * 1989-08-09 1998-06-02 Rhomed Incorporated Polyvalent peptide pharmaceutical applications
US5270197A (en) * 1990-12-20 1993-12-14 The Children's Medical Center Corporation Cells expressing a substantial number of surface high affinity HBGF receptors but relatively few low affinity HBGF binding sites and system for assaying binding to HBGF receptor
GB9101645D0 (en) * 1991-01-25 1991-03-06 British Bio Technology Compounds
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5326695A (en) * 1992-05-15 1994-07-05 Ludwig Institute For Cancer Research Platelet derived growth factor agonists
DE69333950T2 (de) * 1992-05-18 2006-08-17 Genentech, Inc., South San Francisco Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor Liganden
US5763584A (en) 1992-05-18 1998-06-09 Genentech, Inc. Receptor activation with hepatocyte growth factor agonists
US5643756A (en) * 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
US5679673A (en) 1992-09-24 1997-10-21 The United States Of America, Represented By The Department Of Health And Human Services Aralkyl bridged diazabicycloalkane derivatives for CNS disorders
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5674977A (en) 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
US6174530B1 (en) * 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
US6001364A (en) 1993-05-05 1999-12-14 Gryphon Sciences Hetero-polyoxime compounds and their preparation by parallel assembly
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US6284503B1 (en) * 1993-08-20 2001-09-04 University Of Utah Research Foundation Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces
US5952304A (en) * 1993-10-22 1999-09-14 Trigen Limited Platelet-derived growth factor analogues
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5861476A (en) * 1994-02-02 1999-01-19 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5608035A (en) * 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5880096A (en) * 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5786331A (en) * 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US5635597A (en) * 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US6048964A (en) 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US5811151A (en) * 1996-05-31 1998-09-22 Medtronic, Inc. Method of modifying the surface of a medical device
US5965532A (en) 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
IL129379A (en) 1996-10-16 2008-12-29 Zymogenetics Inc Fibroblast growth factor homologues
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US6214795B1 (en) * 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
ATE285415T1 (de) 1997-06-13 2005-01-15 Gryphon Therapeutics Inc Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use
US5955588A (en) * 1997-12-22 1999-09-21 Innerdyne, Inc. Non-thrombogenic coating composition and methods for using same
US6121236A (en) * 1998-03-24 2000-09-19 The Children's Medical Center Corporation Multivalent ligands which modulate angiogenesis
DE19814057B4 (de) * 1998-03-30 2009-01-02 Carl Zeiss Meditec Ag Anordnung zur optischen Kohärenztomographie und Kohärenztopographie
ATE332306T1 (de) * 1998-08-31 2006-07-15 Gryphon Therapeutics Inc Chemische anknüpfung unter einbeziehung von einer lipid-matrix und herstellung von membranpolypeptiden
US7135027B2 (en) * 2002-10-04 2006-11-14 Baxter International, Inc. Devices and methods for mixing and extruding medically useful compositions
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US7671012B2 (en) * 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs

Patent Citations (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3272204A (en) * 1965-09-22 1966-09-13 Ethicon Inc Absorbable collagen prosthetic implant with non-absorbable reinforcing strands
US4193138A (en) * 1976-08-20 1980-03-18 Sumitomo Electric Industries, Ltd. Composite structure vascular prostheses
US5197977A (en) * 1984-01-30 1993-03-30 Meadox Medicals, Inc. Drug delivery collagen-impregnated synthetic vascular graft
US4842575A (en) * 1984-01-30 1989-06-27 Meadox Medicals, Inc. Method for forming impregnated synthetic vascular grafts
US4747848A (en) * 1984-11-30 1988-05-31 Vascutek Limited Vascular grafts
US5830995A (en) * 1988-01-25 1998-11-03 Bristol-Myers Squibb Company Fanphiregulins: a family of heparin-binding epithelial cell growth factors
US5108436A (en) * 1988-09-29 1992-04-28 Collagen Corporation Implant fixation
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US6231892B1 (en) * 1990-10-15 2001-05-15 The Board Of Regents, The University Of Texas System Compositions for coating microcapsules and other surfaces
US5665114A (en) * 1994-08-12 1997-09-09 Meadox Medicals, Inc. Tubular expanded polytetrafluoroethylene implantable prostheses
US5650234A (en) * 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5509899A (en) * 1994-09-22 1996-04-23 Boston Scientific Corp. Medical device with lubricious coating
US6120904A (en) * 1995-02-01 2000-09-19 Schneider (Usa) Inc. Medical device coated with interpenetrating network of hydrogel polymers
US6231600B1 (en) * 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US6491965B1 (en) * 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6458889B1 (en) * 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US6534591B2 (en) * 1995-12-18 2003-03-18 Cohesion Technologies, Inc. Cross-linked polymer compositions and methods for their use
US6096798A (en) * 1996-04-30 2000-08-01 Luthra; Ajay Kumar Non-thrombogenic and anti-thrombogenic polymers
US6406687B1 (en) * 1996-04-30 2002-06-18 Ajay Kumar Luthra Non-thrombogenic and anti-thrombogenic polymers
US5916585A (en) * 1996-06-03 1999-06-29 Gore Enterprise Holdings, Inc. Materials and method for the immobilization of bioactive species onto biodegradable polymers
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6387978B2 (en) * 1996-07-11 2002-05-14 Boston Scientific Corporation Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties
US6306165B1 (en) * 1996-09-13 2001-10-23 Meadox Medicals ePTFE small caliber vascular grafts with significant patency enhancement via a surface coating which contains covalently bonded heparin
US6426332B1 (en) * 1997-02-07 2002-07-30 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
US20010014662A1 (en) * 1997-03-20 2001-08-16 David C Rueger Improved osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
US7041641B2 (en) * 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
US5945457A (en) * 1997-10-01 1999-08-31 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science Process for preparing biologically compatible polymers and their use in medical devices
US6410044B1 (en) * 1998-03-19 2002-06-25 Surmodics, Inc. Crosslinkable macromers
US6270788B1 (en) * 1998-04-03 2001-08-07 Medtronic Inc Implantable medical device
US6258371B1 (en) * 1998-04-03 2001-07-10 Medtronic Inc Method for making biocompatible medical article
US6248057B1 (en) * 1998-07-28 2001-06-19 Innerdyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
US6514534B1 (en) * 1998-08-14 2003-02-04 Incept Llc Methods for forming regional tissue adherent barriers and drug delivery systems
US6818018B1 (en) * 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US7025990B2 (en) * 1998-08-14 2006-04-11 Incept Llc Methods for forming regional tissue adherent barriers and drug delivery systems
US20020115836A1 (en) * 1998-09-22 2002-08-22 Ray Tsang Non-thrombogenic coating composition and methods for using same
US20020160098A1 (en) * 1998-09-22 2002-10-31 Zamora Paul O. Nucleic acid coating compositions and methods
US6596699B2 (en) * 1998-09-22 2003-07-22 Biosurface Engineering Technologies, Inc. Nucleic acid coating compositions and methods
US6630580B2 (en) * 1998-09-22 2003-10-07 Innerdyne, Inc. Silyl and Heparin compositions
US6921811B2 (en) * 1998-09-22 2005-07-26 Biosurface Engineering Technologies, Inc. Bioactive coating composition and methods
US6548634B1 (en) * 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6497729B1 (en) * 1998-11-20 2002-12-24 The University Of Connecticut Implant coating for control of tissue/implant interactions
US6368347B1 (en) * 1999-04-23 2002-04-09 Sulzer Vascutek Ltd. Expanded polytetrafluoroethylene vascular graft with coating
US6309660B1 (en) * 1999-07-28 2001-10-30 Edwards Lifesciences Corp. Universal biocompatible coating platform for medical devices
US6863899B2 (en) * 1999-08-13 2005-03-08 Vita Special Purpose Corporation Composite shaped bodies and methods for their production and use
US6846853B2 (en) * 1999-12-28 2005-01-25 Osteotech, Inc. Calcium phosphate bone graft material, process for making same and osteoimplant fabricated from same
US6585765B1 (en) * 2000-06-29 2003-07-01 Advanced Cardiovascular Systems, Inc. Implantable device having substances impregnated therein and a method of impregnating the same
US6949251B2 (en) * 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
US6984393B2 (en) * 2001-05-07 2006-01-10 Queen's University At Kingston Biodegradable elastomer and method of preparing same
US20040151764A1 (en) * 2001-07-31 2004-08-05 Biosurface Engineering Technologies, Inc. Bioactive medical films
US20050222394A1 (en) * 2002-08-20 2005-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US20080166392A1 (en) * 2002-08-20 2008-07-10 Zamora Paul O Positive Modulator of Bone Morphogenic Protein-2
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US7482427B2 (en) * 2002-08-20 2009-01-27 Biosurface Engineering Technologies, Inc. Positive modulator of bone morphogenic protein-2
US20050196425A1 (en) * 2002-08-20 2005-09-08 Biosurface Engineering Technologies, Inc. Positive modulator of bone morphogenic protein-2
US20040087505A1 (en) * 2002-08-20 2004-05-06 Pena Louis A. Synthetic heparin-binding factor analogs
US20040038348A1 (en) * 2002-08-20 2004-02-26 Pena Louis A. Synthetic heparin-binding growth factor analogs
US20060199764A1 (en) * 2002-08-20 2006-09-07 Biosurface Engineering Technologies, Inc. FGF growth factor analogs
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7468210B1 (en) * 2002-12-10 2008-12-23 Biosurface Engineering Technologies, Inc. Cross-linked heparin coatings and methods
US7241736B2 (en) * 2003-11-10 2007-07-10 Angiotech International Ag Compositions and methods for treating diverticular disease
US20050151764A1 (en) * 2004-01-08 2005-07-14 Eastman Kodak Company Liquid level detection method and apparatus
US7414028B1 (en) * 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US20090143566A1 (en) * 2004-02-04 2009-06-04 Biosurface Engineering Technologies, Inc. Growth Factor Analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7528105B1 (en) * 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
US20060063622A1 (en) * 2004-09-17 2006-03-23 Adidas International Marketing B.V. Bladder
US20090111743A1 (en) * 2005-02-25 2009-04-30 Biosurface Engineering Technologies, Inc. Cysteine-branched heparin-binding growth factor analogs
US20080160169A1 (en) * 2006-06-22 2008-07-03 Zamora Paul O Coating device and method for coating medical device with bioactive peptide

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US20060199764A1 (en) * 2002-08-20 2006-09-07 Biosurface Engineering Technologies, Inc. FGF growth factor analogs
US10611810B2 (en) 2002-08-20 2020-04-07 Ferring International Center S.A. Positive modulator of bone morphogenic protein-2
US20080166392A1 (en) * 2002-08-20 2008-07-10 Zamora Paul O Positive Modulator of Bone Morphogenic Protein-2
US7700563B2 (en) 2002-08-20 2010-04-20 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding factor analogs
US20040087505A1 (en) * 2002-08-20 2004-05-06 Pena Louis A. Synthetic heparin-binding factor analogs
US8163717B2 (en) 2002-08-20 2012-04-24 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US8796212B2 (en) 2002-08-20 2014-08-05 Biosurface Engineering Technologies, Inc. Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis
US10246499B2 (en) 2002-08-20 2019-04-02 Ferring B.V. Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis
US7981862B2 (en) 2003-08-19 2011-07-19 Biosurface Engineering Technologies, Inc. Composition comprising BMP-2 amplifier/co-activator for enhancement of osteogenesis
USRE47115E1 (en) 2003-08-19 2018-11-06 Ferring B.V. Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis
US9670258B2 (en) 2004-02-20 2017-06-06 Ferring B.V. Positive modulator of bone morphogenic protein-2
US8101570B2 (en) 2005-02-22 2012-01-24 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US7820172B1 (en) * 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
US10174088B2 (en) 2006-06-22 2019-01-08 Ferring B.V. Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis
US20080160169A1 (en) * 2006-06-22 2008-07-03 Zamora Paul O Coating device and method for coating medical device with bioactive peptide
US11078244B2 (en) 2006-06-22 2021-08-03 Ferring B.V. Composition and method for delivery of BMP-2 amplifler/co-activator for enhancement of osteogenesis
US9969788B2 (en) * 2006-11-13 2018-05-15 The Brigham And Women's Hospital, Inc. Methods of treating damaged cartilage tissue using growth factors fused to heparin binding sequences
US20160024170A1 (en) * 2006-11-13 2016-01-28 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
CN111936157A (zh) * 2018-02-13 2020-11-13 佛罗里达大学研究基金会 成纤维细胞生长因子类似物及其应用

Also Published As

Publication number Publication date
US20100298218A1 (en) 2010-11-25
JP2008531505A (ja) 2008-08-14
US8101570B2 (en) 2012-01-24
CA2598688A1 (en) 2006-08-31
WO2006091727A3 (en) 2007-03-01
EP1855706A4 (en) 2012-03-28
WO2006091727A2 (en) 2006-08-31
EP1855706A2 (en) 2007-11-21
AU2006216676A1 (en) 2006-08-31
JP4897708B2 (ja) 2012-03-14

Similar Documents

Publication Publication Date Title
US8101570B2 (en) Single branch heparin-binding growth factor analogs
US7528105B1 (en) Heterodimeric chain synthetic heparin-binding growth factor analogs
US7700563B2 (en) Synthetic heparin-binding factor analogs
US7598224B2 (en) Dual chain synthetic heparin-binding growth factor analogs
US7414028B1 (en) Growth factor analogs
US20060024347A1 (en) Bioactive peptide coatings
US9670258B2 (en) Positive modulator of bone morphogenic protein-2
CA2599240C (en) Fgf growth factor analogs
US20090111743A1 (en) Cysteine-branched heparin-binding growth factor analogs
EP1539801B1 (en) Synthetic heparin-binding growth factor analogs

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOSURFACE ENGINEERING TECHNOLOGIES, INC., MARYLAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAKAHASHI, KAZUYUKI;ZAMORA, PAUL O.;REEL/FRAME:017930/0709

Effective date: 20060614

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE